CN114190090A - Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 - Google Patents
Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 Download PDFInfo
- Publication number
- CN114190090A CN114190090A CN202080054905.0A CN202080054905A CN114190090A CN 114190090 A CN114190090 A CN 114190090A CN 202080054905 A CN202080054905 A CN 202080054905A CN 114190090 A CN114190090 A CN 114190090A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- crystalline form
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210564150.XA CN115141205A (zh) | 2019-06-07 | 2020-06-04 | Shp2抑制剂的固体形式 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| US62/858,837 | 2019-06-07 | ||
| PCT/US2020/036137 WO2020247643A1 (en) | 2019-06-07 | 2020-06-04 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210564150.XA Division CN115141205A (zh) | 2019-06-07 | 2020-06-04 | Shp2抑制剂的固体形式 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114190090A true CN114190090A (zh) | 2022-03-15 |
Family
ID=71787182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080054905.0A Pending CN114190090A (zh) | 2019-06-07 | 2020-06-04 | Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 |
| CN202210564150.XA Pending CN115141205A (zh) | 2019-06-07 | 2020-06-04 | Shp2抑制剂的固体形式 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210564150.XA Pending CN115141205A (zh) | 2019-06-07 | 2020-06-04 | Shp2抑制剂的固体形式 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| EP1871762A2 (en) * | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
-
2020
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA56113A (fr) | 2022-04-13 |
| US12528807B2 (en) | 2026-01-20 |
| JP2022534788A (ja) | 2022-08-03 |
| TW202112785A (zh) | 2021-04-01 |
| MX2021014855A (es) | 2022-01-18 |
| CN115141205A (zh) | 2022-10-04 |
| EP3980128A1 (en) | 2022-04-13 |
| IL288568A (en) | 2022-02-01 |
| AU2020288631A1 (en) | 2021-12-09 |
| BR112021022635A2 (pt) | 2022-01-04 |
| JP2025138706A (ja) | 2025-09-25 |
| PH12021552902A1 (en) | 2022-04-04 |
| US11220501B2 (en) | 2022-01-11 |
| WO2020247643A1 (en) | 2020-12-10 |
| KR20220019017A (ko) | 2022-02-15 |
| CA3142430A1 (en) | 2020-12-10 |
| US20210253574A1 (en) | 2021-08-19 |
| SG11202112461QA (en) | 2021-12-30 |
| US20220298159A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12528807B2 (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | |
| CA3098336C (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
| Gao et al. | Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil–saccharin and adefovir dipivoxil–nicotinamide cocrystals | |
| CN113354649B (zh) | 一种新的晶型 | |
| JP6230709B2 (ja) | Syk阻害剤の多形体 | |
| JP6218253B2 (ja) | ロルラチニブ遊離塩基の結晶形態 | |
| CN116925075A (zh) | 一种喹唑啉化合物的晶型、盐型及其制备方法 | |
| CN107848991B (zh) | (z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸的固体形式 | |
| TW202545956A (zh) | 吡啶並嘧啶類衍生物的晶型、製備方法及其應用 | |
| CN103459394A (zh) | 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物 | |
| CN111093651A (zh) | Ido抑制剂的无定形和结晶形式 | |
| US20210032218A1 (en) | Succinate forms and compositions of bruton's tyrosine kinase inhibitors | |
| Neelam et al. | Physicochemical aspects and comparative analysis of Voxelotor and its salt and cocrystal | |
| JP2020534331A (ja) | ((1s,2s,4r)−4−{4−[(1s)−2,3−ジヒドロ−1h−インデン−1−イルアミノ]−7h−ピロロ[2,3−d]ピリミジン−7−イル}−2−ヒドロキシシクロペンチル)メチルスルファメートの共結晶形態、その製剤及び使用 | |
| CN106279126B (zh) | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 | |
| Chai et al. | Structural analysis and properties of two novel pharmaceutical salts of letermovir | |
| HK40077975A (zh) | Shp2抑制剂的固体形式 | |
| CN110944995B (zh) | 5-溴-2,6-二(1h-吡唑-1-基)嘧啶-4-胺和新盐的晶型 | |
| HK40068870A (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor | |
| TW202039511A (zh) | Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物 | |
| Ito et al. | Desolvation behavior of indinavir sulfate ethanol and follow-up by terahertz spectroscopy | |
| Łaszcz et al. | Structural and physicochemical studies of olopatadine hydrochloride conformational polymorphs | |
| CN114127071A (zh) | 激酶抑制剂的多晶型、含有该化合物的药物组合物、制备方法、及应用 | |
| US8691981B2 (en) | Crystalline forms of (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide | |
| US10072029B2 (en) | Crystalline form of a proteasome inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40068870 Country of ref document: HK |